Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 991-1003

  Vital, Ana Luísa ^a,b   Tabernero, Maria Dolores ^c,d,e   Castrillo, Abel ^c   Rebelo, Olinda ^f   Tão, Hermínio ^f   Gomes, Fernando ^f   Nieto, Ana Belen ^d   Oliveira, Catarina Resende ^a   Lopes, Maria Celeste ^a,b   Orfao, Alberto ^d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d CSIC   (Spain)

^e University Hospital of Coimbra ^*  (Spain)

^f CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Cytogenetics; FISH; Gene expression; Glioblastoma; Glioma; Histopathology; Microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ADULT; AGED; APOPTOSIS; ASTROCYTOMA; CANCER GRADING; CELL CLONE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA REPAIR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPE; MALE; MICROARRAY ANALYSIS; MIXED TUMOR; OLIGODENDROGLIOMA; REVIEW; SIGNAL TRANSDUCTION; TRISOMY 7; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CLUSTER ANALYSIS; CYTOGENETICS; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; YOUNG ADULT;

EID: 78650163455     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq050     Document Type: Review

References (49)

1. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin Cancer Res. 2004;10(23):7820-7826.
2. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117.
3. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1):49-56.
4. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2003;2(3):242-247.
5. Czernicki T, Zegarska J, Paczek L, et al. Gene expression profile as a prognostic factor in high-grade gliomas. Int J Oncol. 2007;30(1):55-64.
6. El-Jawahri A, Patel D, Zhang M, Mladkova N, Chakravarti A. Biomarkers of clinical responsiveness in brain tumor patients: progress and potential. Mol Diagn Ther. 2008;12(4):199-208.
7. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 2006;65(12):1181-1188.
8. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998;24(5):381-388.
9. Nakamura M, Shimada K, Ishida E, Nakase H, Konishi N. Genetic analysis to complement histopathological diagnosis of brain tumors. Histol Histopathol. 2007;22(3):327-335.
10. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006;65(9):846-854.
11. Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, et al. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer. 2008;98(11):1830-1838.
12. Backlund LM, Nilsson BR, Liu L, Ichimura K, Collins VP. Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer. 2005;93(1):124-130.
13. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015-3024.
14. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003;22(31):4918-4923. (Pubitemid 36981282)
15. Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002;1(13): 1229-1236.
16. Persson O, Krogh M, Saal LH, et al. Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol. 2007;85(1):11-24.
17. Shirahata M, Iwao-Koizumi K, Saito S, et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res. 2007;13(24):7341-7356.
18. van den Boom J, Wolter M, Kuick R, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol. 2003;163(3): 1033-1043.
19. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64(18): 6503-6510.
20. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63(7):1602-1607.
21. Vital AL, Tabernero MD, Crespo I, et al. Intratumoral patterns of clonal evolution in gliomas. Neurogenetics. 2009;11(4):227-239.
22. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. In: Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK eds. WHO Classification of Tumours of the Central Nervous System. WHO classification. WHO grading Astrocytic Tumours. Oligodendroglial Tumours, Chap. 08-67. IARC: Lyon 2007.
23. Sayagues JM, Tabernero MD, Maillo A, Espinosa A, Rasillo A, Diaz P, et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions? J Mol Diagn. 2004;6(4):316-325.
24. Tabernero MD, Espinosa AB, Maillo A, Rebelo O, Vera JF, Sayagues JM, et al. Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist. 2007;12(10):1225-1236.
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2): 249-264.
26. Breiman L. Random Forests. Mach Learn. 2001;45(1):5-32.
27. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol. 2000;156(2):425-432.
28. Tena-Suck ML, Moreno-Jimenez S, Alonso M, Aguirre-Crux L, Sanchez A. Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. Ann Diagn Pathol. 2008;12(5):313-321.
29. Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al. Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 2008;1201:161-166.
30. Cabreiro F, Picot CR, Perichon M, Castel J, Friguet B, Petropoulos I. Overexpression of mitochondrial methionine sulfoxide reductase B2 protects leukemia cells from oxidative stress-induced cell death and protein damage. J Biol Chem. 2008;283(24):16673-16681.
31. Peng Y, Li CX, Chen F, Wang Z, Ligr M, Melamed J, et al. Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol. 2008;172(1): 225-235.
32. Steigemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S, et al. Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell. 2009;136(3):473-484.
33. Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, Pico AR, et al. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1368-1373.
34. Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005;120(5):675-685.
35. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28(6): 1133-1139.
36. Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, Keller JR, Olafsson K, Egeland T, et al. Gene expression analysis of hematopoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells. 2007;25(6):1498-1506.
37. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5): 1087-1098.
38. Arslantas A, Artan S, Oner U, Muslumanoglu MH, Ozdemir M, Durmaz R, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res. 2007;13(1):39-46.
39. Dietschy T, Shevelev I, Stagljar I. The molecular role of the Rothmund-Thomson-, RAPADILINO- and Baller-Gerold-gene product, RECQL4: recent progress. Cell Mol Life Sci. 2007;64(7-8):796-802.
40. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1):e10.
41. Gdynia G, Lehmann-Koch J, Sieber S, Tagscherer KE, Fassl A, Zentgraf H, et al. BLOC1S2 interacts with the HIPPI protein and sensitizes NCH89 glioblastoma cells to apoptosis. Apoptosis. 2008;13(3):437-447.
42. Jendrossek V, Kugler W, Erdlenbruch B, Eibl H, Lakomek M. Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine. Int J Oncol. 2001;19(4):673-680.
43. Chang Y, Berenson JR, Wang Z, Deuel TF. Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells. Biochem Biophys Res Commun. 2006;351(2):336-339.
44. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, 2nd, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008;339(1):74-81.
45. Belda-Iniesta C, de Castro Carpeno J, Sereno M, Gonzalez-Baron M, Perona R. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol. 2008;10(2):73-77.
46. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA. 2009;106(8):2712-2716.
47. Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 2008;123(12):2955-2960.
48. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem. 2006;281(25):17492-17500.
49. Hoelzinger DB, Nakada M, Demuth T, Rosensteel T, Reavie LB, Berens ME. Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion. J Neurooncol. 2008;86(3):297-309.